Summit Therapeutics Inc. (SMMT) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Summit Therapeutics (SMMT) Q2 2026: R&D Spend Climbs 24% as Avonisimab Heads Toward FDA Decision
July 24, 2026
-
Summit Therapeutics (SMMT) Q4 2025: Harmony 3 Interim PFS Analysis Accelerates Regulatory Path
February 25, 2026
-
Sandvik (SMMT) Q3 2025: Mining Equipment Orders Surge 75%, Extending Backlog Momentum
October 21, 2025
-
Summit Therapeutics (SMMT) Q1 2025: Harmony 2 OS Hazard Ratio at 0.78 Signals Global Lung Cancer Ambition
July 04, 2025